A US policy perspective on oral preexposure prophylaxis for HIV
- PMID: 21493945
- PMCID: PMC3093264
- DOI: 10.2105/AJPH.2010.300066
A US policy perspective on oral preexposure prophylaxis for HIV
Abstract
Orally administered preexposure prophylaxis is an innovative and controversial HIV prevention strategy involving the regular use of antiretroviral medications by uninfected individuals. Antiretroviral medications protect against potential HIV infection by reducing susceptibility to the virus. Recent clinical trial results indicate that preexposure prophylaxis can be safe and efficacious for men who have sexual intercourse with men, yet there remain policy considerations surrounding costs, opportunity costs, and ethical issues that must be addressed before broad implementation in the United States.
References
-
- Garcia-Lerma JG, Paxton L, Kilmarx PH, Heneine W. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci. 2010;31(2):74–81 - PubMed
-
- AIDS Vaccine Advocacy Coalition Ongoing PrEP trials, PrEP trials map. Available at: http://www.avac.org/ht/d/sp/i/3507/pid/3507d/sp/i/3507/pid/3507. Accessed June 3, 2010
-
- AIDS Vaccine Advocacy Coalition Summary from the AVAC Think Tank on PrEP financing in the US. Available at: http://www.avac.org/ht/d/sp/a/GetDocumentAction/i/3529. Accessed June 3, 2010
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
